180 related articles for article (PubMed ID: 14576853)
1. The role of p53 in chemosensitivity and radiosensitivity.
El-Deiry WS
Oncogene; 2003 Oct; 22(47):7486-95. PubMed ID: 14576853
[TBL] [Abstract][Full Text] [Related]
2. Targeting p53 for enhanced radio- and chemo-sensitivity.
Lu C; El-Deiry WS
Apoptosis; 2009 Apr; 14(4):597-606. PubMed ID: 19259822
[TBL] [Abstract][Full Text] [Related]
3. Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells.
Böhnke A; Westphal F; Schmidt A; El-Awady RA; Dahm-Daphi J
Int J Radiat Biol; 2004 Jan; 80(1):53-63. PubMed ID: 14761850
[TBL] [Abstract][Full Text] [Related]
4. The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy AR; Bristow RG
Cancer Metastasis Rev; 2004; 23(3-4):237-57. PubMed ID: 15197326
[TBL] [Abstract][Full Text] [Related]
5. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
[TBL] [Abstract][Full Text] [Related]
6. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
[TBL] [Abstract][Full Text] [Related]
7. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?
Levesque AA; Eastman A
Carcinogenesis; 2007 Jan; 28(1):13-20. PubMed ID: 17088261
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. The genetics of the p53 pathway, apoptosis and cancer therapy.
Vazquez A; Bond EE; Levine AJ; Bond GL
Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
[TBL] [Abstract][Full Text] [Related]
13. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
15. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer.
Ohtsuka T; Liu XF; Koga Y; Kitajima Y; Nakafusa Y; Ha CW; Lee SW; Miyazaki K
Oncogene; 2006 Mar; 25(12):1807-11. PubMed ID: 16331272
[TBL] [Abstract][Full Text] [Related]
16. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
17. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
Resnick-Silverman L; Manfredi JJ
J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
[TBL] [Abstract][Full Text] [Related]
18. Homeobox Msx1 interacts with p53 tumor suppressor and inhibits tumor growth by inducing apoptosis.
Park K; Kim K; Rho SB; Choi K; Kim D; Oh SH; Park J; Lee SH; Lee JH
Cancer Res; 2005 Feb; 65(3):749-57. PubMed ID: 15705871
[TBL] [Abstract][Full Text] [Related]
19. p53 and its downstream proteins as molecular targets of cancer.
Sun Y
Mol Carcinog; 2006 Jun; 45(6):409-15. PubMed ID: 16652354
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
